XENE NASDAQ
Xenon Pharmaceuticals Inc.
1W: -3.4%
1M: -4.5%
3M: +28.2%
YTD: +21.6%
1Y: +72.2%
3Y: +31.6%
5Y: +212.1%
$54.17
+0.05 (+0.09%)
Weekly Expected Move ±4.4%
$50
$52
$54
$57
$59
Overview
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Revenue Segmentation
By Product / Service
Revenue by Segment (5-Year Trend)
Income Trends
Revenue
$8M
+0.0% ▲
5Y CAGR: -25.3%
Gross Profit
$5M
+293.6% ▲
5Y CAGR: -31.2%
Operating Income
-$373M
-33.6% ▼
Net Income
-$346M
-47.6% ▼
EPS (Diluted)
$-4.36
-44.9% ▼
EBITDA
-$342M
-45.2% ▼
Profit Margins
Year-over-Year Growth
View Full Income Statement
| Line Item | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Revenue | $18M | $9M | $0 | $0 | $8M |
| YoY Growth | -42.7% | -48.8% | -100.0% | +0.0% | +0.0% |
| Cost of Revenue | $0 | $0 | $168M | $3M | $3M |
| Gross Profit | $18M | $9M | -$168M | -$3M | $5M |
| Gross Margin | 100.0% | 100.0% | — | — | 66.1% |
| R&D Expenses | $75M | $106M | $168M | $210M | $301M |
| SG&A Expenses | $22M | $33M | $47M | $69M | $80M |
| Operating Expenses | $97M | $139M | $47M | $277M | $378M |
| Operating Income | -$79M | -$129M | -$214M | -$279M | -$373M |
| Operating Margin | -428.4% | -1368.9% | — | — | -4974.3% |
| Interest Expense | $0 | $0 | $0 | $0 | $0 |
| Income Before Tax | -$79M | -$125M | -$183M | -$238M | -$345M |
| Tax Expense | -$6K | $118K | -$292K | -$4M | $1M |
| Net Income | -$79M | -$125M | -$182M | -$234M | -$346M |
| Net Margin | -427.8% | -1328.9% | — | — | -4612.1% |
| EPS (Diluted) | $-1.77 | $-2.06 | $-2.73 | $-3.01 | $-4.36 |
| EBITDA | -$78M | -$128M | -$211M | -$236M | -$342M |
| Shares Outstanding | 44M | 61M | 67M | 78M | 79M |